Ricardo is Helping to Accelerate Europe’s Transformation to a Climate-resilient Future
27.7.2023 02:05:00 EEST | Business Wire | Press release
Ricardo, a global strategic environmental and engineering consulting company, is leading the EU Mission Implementation Platform for Adaptation to Climate Change (MIP4Adapt), providing support to the European Commission and everyone delivering the EU Mission on Adaptation to Climate Change.
The Mission is focused on supporting European regions and local authorities to accelerate their adaptation to climate change and building climate resilience. This is of vital importance given the fact that the impacts of climate change are already happening, and more regularly – as evidenced by extreme weather events already increasing in magnitude and frequency which are having direct and indirect impacts on our environment, society, and economy. In turn, these impacts may increasingly lead to transnational spill-over effects on international trade, resource competition, regional conflict, migration, and the spread of pests and diseases.
Ricardo’s experts across Europe are working closely with the European Commission in delivering MIP4Adapt – which is the result of a public procurement process - with the work commitment starting in 2023 and running until 2025. MIP4Adapt’s core team also includes experts from: Fresh Thoughts Consulting, Icatalist, the European Federation of Agencies and Regions for Energy and Environment – FEDARENE, and Joanneum Research, as well as experts from across Europe able to deliver technical assistance to the regional and local authorities in all 27 EU Member States.
In leading MIP4Adapt, Ricardo is facilitating the development of a community of practice to promote the exchange of knowledge and experiences and enable regional and local authorities across Europe to strengthen coordination and collaboration around climate adaptation. The community includes the 308 regional and local authorities that are signatories to the Mission Charter, covers approximately 40% of Europe’s land area and population, and is committed to striving towards climate resilience by 2030. In addition, it comprises relevant EU-funded research and innovation projects, the European Commission and other relevant European institutions, national authorities, and Friends of the Mission, including research institutions and businesses.
Through MIP4Adapt, Ricardo is also delivering technical assistance to the regional and local authorities that are Charter signatories. This includes helping them to: develop their climate adaptation plans; identify appropriate climate adaptation demonstration projects; identify and access suitable finance and funding for implementation of their plans and demonstration projects; and stimulate engagement and mobilisation of citizens and stakeholders in climate adaptation.
Richard Smithers, Director of MIP4Adapt and Ricardo’s international lead on climate adaptation said: “Ricardo’s delivery of MIP4Adapt builds upon our support for the European Commission over the last decade regarding development and implementation of the EU Adaptation Strategy. It also draws on Ricardo’s wide-ranging experience of supporting all aspects of climate adaptation planning at all scales in over 40 countries beyond Europe, and on the expertise of our wider team. Through our leadership of MIP4Adapt, our desire is to help to amplify the Mission’s overall impact across mainland Europe, so it is greater than the sum of individual actions.”
Ends
Notes to editors:
About the EU Mission on Adaptation to Climate Change
Further information about the Mission and MIP4Adapt can be found at the Mission Portal, Visit https://climate-adapt.eea.europa.eu/en/mission
About the core team for MIP4Adapt
Ricardo’s core team for MIP4Adapt also includes experts from Fresh Thoughts Consulting (leading access to the best available knowledge, tools and methods in association with the European Environment Agency), Icatalist (leading on stakeholder and citizen engagement), the European Federation of Agencies and Regions for Energy and Environment – FEDARENE (supporting networking between regional and local authorities) and Joanneum Research (fostering links between the EU Mission on Adaptation to Climate Change and the four other EU Missions).
About Ricardo
Ricardo plc is a global strategic, environmental, and engineering consulting company, listed on the London Stock Exchange. With over 100 years of engineering excellence and employing close to 3,000 employees in more than 20 countries, we provide exceptional levels of expertise in delivering leading-edge and innovative cross-sector sustainable products and solutions. Every day, we enable our customers to solve the most complex and dynamic challenges to help achieve a safe and sustainable world. Visit www.ricardo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230726541878/en/
Contact information
Kathryn Bellamy
Group Senior Communications Manager
Ricardo plc
Email: kathryn.bellamy@ricardo.com
Telephone: +44(0)7921 941824
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom